In conclusion, we describe the identification of several FDA approved drugs as VMAT2 inhibitors which are interesting from a drug repurposing perspective aimed at for instance treatment of TD and Huntington’s chorea. The gene discussed is SLC18A2; the disease is Huntington disease.